Downregulation of RBBP6 variant 1 during arsenic trioxide-mediated cell cycle arrest and curcumin-induced apoptosis in MCF-7 breast cancer cells
Autor: | Kagiso Laka, Zukile Mbita, Lilian Makgoo |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Cell cycle checkpoint G2/M arrest chemistry.chemical_element splicing 03 medical and health sciences chemistry.chemical_compound breast cancer 0302 clinical medicine Breast cancer Downregulation and upregulation medicine Arsenic trioxide Arsenic RBBP6 apoptosis medicine.disease arsenic trioxide 030104 developmental biology chemistry MCF-7 Apoptosis 030220 oncology & carcinogenesis Curcumin Cancer research Research Article Biotechnology |
Zdroj: | Future Science OA |
ISSN: | 2056-5623 |
DOI: | 10.2144/fsoa-2019-0047 |
Popis: | Aim: To determine the expression patterns of the RBBP6 spliced variants during arsenic trioxide-mediated cell cycle arrest and curcumin-induced apoptosis in MCF-7 cells. Materials & methods: As2O3 and curcumin were used to study cytotoxicity, cell cycle arrest, apoptosis and the expression of RBBP6 variants. The MUSE Cell Analyser was used to analyze cell cycle arrest, apoptosis and multicaspase activity while apoptosis was further confirmed using microscopy. Semi-quantitative RT-PCR was employed to quantitate the expression of the RBBP6 variants. Results: This study showed that the MCF-7 cells expressed RBBP6 variant 1 but lacked both variant 2 and variant 3. Both As2O3 and curcumin significantly downregulated RBBP6 variant 1 (p < 0.001). Conclusion: RBBP6 variants are promising therapeutic targets. Lay abstract Understanding how breast cancer develops remains to be fully understood. It is known that genes play a pivotal role in the carcinogenesis process. The RBBP6 gene, which has different variants, has been reported to be involved in cancer development but it remains unclear which RBBP6 product is involved in cancer development. This study has demonstrated that there are RBBP6 variants that are pro-carcinogenic and those that are anti-carcinogenic. This study further showed that arsenic trioxide and curcumin lowered the expression of the RBBP6 splice variant 1 in MCF-7 breast cancer cells. Therefore, targeting RBBP6 variants for future drug development is a promising strategy. |
Databáze: | OpenAIRE |
Externí odkaz: |